Add like
Add dislike
Add to saved papers

Titanocenes as anticancer agents: recent insights.

Medicinal Chemistry 2016 December 29
BACKGROUND: Enormous success of antitumor agent cisplatin initiated interest in other organometallic complexes. A subclass of organometallic compounds termed metallocenes, characterized by a transition metal central atom (M) bound to cyclopentadienide (Cp-/[C5H5]-) ligands with the basic formula Cp2M, has gained increasing interest as promising anticancer agents.

OBJECTIVES: This review is aimed at a progress in the development of organometallic titanium-based compounds focusing primarily on the evaluation of their cytotoxic activity and mechanism of action in relation to potential utilization as anticancer drugs.

RESULTS: Metallocenes bearing titanium as central atom were sorted according to their structure and modifications and their anticancer activity is further discussed.

CONCLUSION: Titanocenes represent family of promising compounds exerting cytostatic activity. We suggest that their application not only as separate agents, but also in combination with newly developed carriers, e.g. nanomaterials, may lead to improvement of their delivery into tumor cells and following utilization in cancer treatment.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app